Today, the U.S. Food and Drug Administration approved Striverdi Respimat (olodaterol) inhalation spray to treat patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema that are experiencing airflow obstruction. Striverdi Respimat can be used once…
FDA approves Striverdi Respimat to treat chronic obstructive pulmonary disease
Thursday, July 31, 2014
FDA approves Striverdi Respimat to treat chronic obstructive pulmonary disease
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment